F. Yüksel

发表

The Effect of Anthracycline-Based (Epirubicin) Adjuvant Chemotherapy on Plasma TAFI and PAI-1 Levels in Operable Breast Cancer

M. Alakavuklar, B. Demirkan, A. Alacacıoğlu, 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?

F. Demirkan, I. Alacacioglu, M. A. Özcan, 2018, Turkish journal of haematology : official journal of Turkish Society of Haematology.

The Effect of the Acute Submaximal Exercise on Thrombin Activatable Fibrinolysis Inhibitor Levels in Young Sedentary Males

C. Bediz, I. Aksu, F. Demirkan, 2011, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

The investigation of relationship between joint findings and serum angiogenic and inflammatory factor levels in severe hemophilia A patients

C. Vergin, H. Ören, G. Irken, 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Usefulness of preprocedural soluble CD40 ligand for predicting restenosis after percutaneous coronary intervention in patients with stable coronary artery disease.

N. Barış, B. Akdeniz, M. Ozcan, 2006, The American journal of cardiology.

Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders.

B. Undar, F. Demirkan, T. Demir, 2003, Thrombosis research.

The evaluation of protein Z levels of children with acute lymphoblastic leukaemia during induction therapy

C. Vergin, H. Ören, G. Irken, 2013, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Evaluation of plasma tissue factor and tissue factor pathway inhibitor levels in childhood hemangiomas

N. Olgun, H. Ören, G. Irken, 2006, Pediatric blood & cancer.

Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women.

H. Ozsan, B. Undar, F. Demirkan, 2004, Thrombosis research.

Plasma Thrombin Activatable Fibrinolysis Inhibitor Levels in Behçet ’ s Disease

S. Akar, N. Akkoç, F. Yüksel, 2007 .

Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease

M. Akarsu, F. Demirkan, F. Yüksel, 2001, American journal of hematology.

Plasma Transforming Growth Factor β1 Levels in Thrombocytopenic and Nonthrombocytopenic Neonates

H. Ören, G. Irken, M. Duman, 2003, Neonatology.

Plasma levels of thrombin activatable fibrinolysis inhibitor antigen in active and inactive inflammatory bowel disease.

M. Akarsu, F. Demirkan, F. Yüksel, 2006, Turkish journal of haematology : official journal of Turkish Society of Haematology.

B-cell-activating factor, a proliferation inducing ligand and co-stimulatory molecules in the pathogenesis of immune thrombocytopenia in childhood

C. Vergin, H. Ören, G. Irken, 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion

Y. Baran, F. Demirkan, F. Yüksel, 2015, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.